Papers/CAERS:2018-CFS-000217
openFDA CAERS report 2018-CFS-000217
CON-CRETThe record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
creatine — increases serum creatinine concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“CAERS report 2018-CFS-000217: Blood creatinine increased following CON-CRET.”
Quoted verbatim from openFDA CAERS report 2018-CFS-000217. - Study
- spontaneous report · not in humans
- Population
- not applicable — single spontaneous report, no defined population (age 29 year(s), Male)
openFDA CAERS report 2018-CFS-000217CAERS:2018-CFS-000217Permalink
creatine — increases serum creatine kinase activity
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“CAERS report 2018-CFS-000217: Blood creatine phosphokinase increased following CON-CRET.”
Quoted verbatim from openFDA CAERS report 2018-CFS-000217. - Study
- spontaneous report · not in humans
- Population
- not applicable — single spontaneous report, no defined population (age 29 year(s), Male)
openFDA CAERS report 2018-CFS-000217CAERS:2018-CFS-000217Permalink